Assessing the Efficacy of High-Dose Rifampicin plus Albendazole against Onchocerciasis
No Thumbnail Available
Date
2026
Journal Title
Journal ISSN
Volume Title
Publisher
KNUST
Abstract
The dataset provides de identified participant data from the ASTAWOL clinical trial (https://kccr-ghana.org/research-impact/research-groups/filariasis-2/), a phase II pilot study investigating the efficacy and safety of high-dose rifampicin (RIF) plus albendazole (ALB) in treating onchocerciasis. The trial was conducted in the Sefwi Akontombra District, Ghana – an area endemic for this parasitic disease.
Study Design: Participants (adults aged 18–55 with confirmed onchocercomata and microfilaria) were randomized into four treatment arms: RIF+ALB (7 or 14 days), ALB alone (14 days), and No Treatment, alongside six-month ivermectin administration.
Data Included: The dataset encompasses comprehensive clinical data including demographic characteristics, treatment allocation, adverse events, laboratory safety parameters, skin microfilarial densities, Wolbachia depletion measurements via qPCR, and detailed immunohistology analysis of surgically removed onchocercomata tissue to assess embryogenesis and worm viability.
Access and Use: Access to this dataset is subject to reasonable requests to the corresponding author, obtaining relevant institutional ethics approval, and proper acknowledgement and citation of the original study.
Description
A dataset that provides de-identified participant data from the ASTAWOL clinical trial phase II pilot study investigating the efficacy and safety of high-dose rifampicin (RIF) plus albendazole (ALB) in treating onchocerciasis. Funded by EDCTP2; Grant Code TMA2018SF-2451.
Keywords
Citation
Ahiadorme, M. et al. (2026). Dataset on assessing the Efficacy of High-Dose Rifampicin plus Albendazole against Onchocerciasis. (ASTAWOL clinical trial dataset).